(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 April 2007 (12.04.2007)

PCT

(10) International Publication Number
WO 2007/040438 A3

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 19/08* (2006.01)
A61K 31/437 (2006.01) *A61P 25/00* (2006.01)
A61K 31/444 (2006.01) *A61P 25/28* (2006.01)
A61K 31/501 (2006.01) *A61P 3/10* (2006.01)
A61K 31/551 (2006.01)

(21) International Application Number:
PCT/SE2006/001114

(22) International Filing Date: 2 October 2006 (02.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0502172-0 3 October 2005 (03.10.2005) SE

(71) Applicant *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ARVIDSSON, Per I** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **ARZEL, Erwan** [FR/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **BURROWS, Jeremy** [GB/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **CLAESSON, Martina** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **RAY, Colin** [GB/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **REIN, Tobias** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **ROTTICCI, Didier** [FR/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **SÖDERMAN, Peter** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
31 May 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS



(I)

(57) Abstract: The present invention relates to new compounds of formula (I) Wherein X is or Y; as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

WO 2007/040438 A3